ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Antibodies"

  • 2015 American Transplant Congress

    Bortezomib-Based Multi-Modality Protocol for Donor-Specific Antibody Treatment in Lung Transplant Recipients

    M. Vacha, A. Hulbert, J. Byrns, C. Benedetti, A. Finlen Copeland, A. Gray, S. Palmer, L. Snyder.

    Duke University Hospital, Durham, NC.

    Background Donor specific antibodies (DSAs) after lung transplant have been implicated in the development of chronic lung allograft dysfunction and mortality. The ideal treatment strategy…
  • 2015 American Transplant Congress

    Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy After Heart Transplant?

    M. Kittleson, J. Patel, F. Liou, S. Siddiqui, J. Yabuno, D. Chang, D. Ramzy, L. Czer, F. Esmailian, N. Reinsmoen, J. Kobashigawa.

    Cedars-Sinai Heart Institute, Los Angeles, CA.

    Purpose: Donor specific antibodies (DSA) following heart transplant has been reported to be associated with increased development of cardiac allograft vasculopathy (CAV) and risk of…
  • 2015 American Transplant Congress

    Multicenter Validation of a Molecular Diagnostic for Antibody-Mediated Rejection in Formalin-Fixed Paraffin-Embedded Human Renal Allograft Biopsies

    B. Adam,1 B. Afzali,1 N. Shah,1 K. Dominy,2 R. Gill,1 L. Hidalgo,1 P. Campbell,1 C. Roufosse,2 M. Mengel,1 B. Sis.1

    1University of Alberta, Edmonton, Canada; 2Imperial College, London, United Kingdom.

    Background: In 2013, the Banff classification adopted molecular diagnostics as an adjunct for the diagnosis of antibody-mediated rejection (ABMR) in renal allografts. The NanoString gene…
  • 2015 American Transplant Congress

    Incidence, Timing, and Consequence of De Novo Donor Specific Antibody in Intestinal Transplantation

    C. Matsumoto, J. Hawksworth, S. Kozlowski, S. Rosen-Bronsen, A. Kromer, M. Grafals, N. Yazgi, S. Kaufman, K. Khan, R. Girlanda, E. Island, C. Desai, T. Fishbein.

    Center for Intestinal Care and Transplant, Medstar Georgetown Transplant Institute, Washington, DC.

    The development of denovo Donor specific antibody (dnDSA) in intestinal transplantation (ITx) remains largely unknown. We conducted a prospective and longitudinal analysis of adult and…
  • 2015 American Transplant Congress

    Kidney Transplantation (KTx) With Positive Crossmatch (XM) but No Donor Specific Antibody (DSA)

    J. Verbesey, O. Timofeeva, L. Dong, B. Javaid, G. Monica, A. Gilbert, J. Moore, P. Weems, S. Ghasemian, S. Rosen-Bronson, M. Cooper.

    MedStar Georgetown Transplant Institute, Washington, DC.

    Purpose: Prior to KTx, a XM is performed between the intended recipient and donor. This XM can be positive despite no DSA. It can be…
  • 2015 American Transplant Congress

    Pro-Inflammatory Actions of New Non-HLA Antibodies Targeting Protease-Activated Receptor (PAR-1)

    R. Catar,1 C. Luecht,1 M. Simon,1 A. Philippe,1 A. Kusch,1 M. Szczepek,2 P. Hildebrand,2 P. Scheerer,2 D. Dragun.1

    1Nephrology and Intensive Care Medicine, Charité, Berlin, Germany; 2Institute of Medical Physics and Biophysics, Charité, Berlin, Germany.

    Microvascular endothelium is major target for antibodies directed against HLA and non-HLA antigens. Functional antibodies targeting G-protein coupled receptors (GPCRs) such as AT1R or ETAR…
  • 2015 American Transplant Congress

    Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation

    F. Liou, M. Kittleson, J. Patel, S. Siddiqui, M. Luu, B. Kearney, D. Ramzy, D. Chang, L. Czer, N. Reinsmoen, J. Kobashigawa.

    Cedars-Sinai Heart Institute, Los Angeles, CA.

    Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…
  • 2015 American Transplant Congress

    A New Diagnostic Tool for Antibody Mediated Rejection in Heart and Lung Transplantation: Intragraft Donor Specific Anti-HLA Antibodies Detection

    J. Olagne,1,2,3 A. Parissiadis,2 N. Froelich,2 S. Caillard,1 M.-P. Chenard,3 E. Epailly,4 H. Kremer,4 T. Degot,5 S. Hirschi,5 R. Kessler,5 B. Moulin.1

    1Service de Néphrologie - Transplantation, Centre Hospitalier Universitaire, Strasbourg, France; 2Laboratoire d'Histocompatibilité, Etablissement Français du Sang, Strasbourg, Alsace, France; 3Département de Pathologie, Centre Hospitalier Universitaire, Strasbourg, France; 4Service de Cardiologie, Centre Hospitalier Universitaire, Strasbourg, France; 5Service de Pneumologie, Centre Hospitalier Universitaire, Strasbourg, France.

    INTRODUCTION: Antibody mediated rejection (AMR) is one of the causes of dysfunction and graft loss. The limited histological features, with a weak sensibility of c4d,…
  • 2015 American Transplant Congress

    De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)

    J. Kahwaji, P. Wongsaroj, J. Choi, A. Peng, R. Villicana, S. Jordan, A. Vo.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: The primary treatment for polyomavirus BK viral infection (BKV) is a reduction in immunosuppression exposure. However this can lead to rejection and development of…
  • 2015 American Transplant Congress

    Mycophenolic Acid Area-Under-Curve (MPA AUC) Levels Sufficient to Prevent Donor-Specific Antibody (DSA) Formation Are Not Associated With Higher Rates of CMV/EBV/BK Viral Infections

    S. Narins, D. Ladie, R. Saylor, E. Richards, H. Yang, M. Waybill.

    PinnacleHealth, Harrisburg, PA.

    Background: Prevention of DSA formation and antibody-mediated rejection mandates therapeutic doses of immunosuppressive agents, including MPA. We have shown that MPA AUC monitoring and dose…
  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences